Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome

Title: Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome

Volume: 15 Issue: 29

Author(s): M. Florentin, M. S. Elisaf, D. P. Mikhailidis and E. N. Liberopoulos

Affiliation:

Keywords: Bile acid sequestrants, ezetimibe, fibrates, metabolic syndrome, niacin, orlistat, rimonabant, statins

Abstract: Metabolic syndrome (MetS) is a cluster of risk factors, each one individually associated with increased cardiovascular disease risk. Treatment of all components of MetS is expected to result in reduced risk. Treatment of MetS mainly includes lifestyle changes. In addition, drug therapy may be considered, especially combinations of different drugs, in order to tackle all the features of MetS. We review the therapeutic strategies currently used for obesity and dyslipidemia treatment in patients with MetS, with a focus on drug combinations.

Cite this article as:

Florentin M., Elisaf S. M., Mikhailidis P. D. and Liberopoulos N. E., Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome, Current Pharmaceutical Design 2009; 15 (29) . https://dx.doi.org/10.2174/138161209789105054